Poziotinib Fails To Get FDA Panel Support Though Members Not As Dubious As Agency

 
• By Brenda Sandburg
  
Lung cancer
Spectrum's lung cancer drug fails to win backing of US FDA advisory committee • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers